Healwell AI’s Q1 Report Looms as the Company Bets Big on Software and a SpaceX Payday

Healwell AI reports Q1 results May 7 amid weak guidance, a transformative shift to pure AI software, and potential C$15M+ gain from SpaceX-linked investment.

Investors are bracing for a bumpy ride when Healwell AI releases its first-quarter results on May 7. The Canadian health-tech firm has already warned that this will be the weakest quarter of the year, with seasonal headwinds weighing on the top line. But beneath the subdued guidance lies a story of transformation—and a potential windfall from an unlikely source.

A Business in Transition

Healwell is in the midst of shedding its clinical operations to emerge as a pure-play artificial intelligence software company. The centerpiece of this pivot is the planned sale of HEAL Access Canada to AI Maverick Intel, with a binding agreement expected by the end of May. The deal would leave Healwell focused entirely on recurring subscription revenue from its AI platforms.

The groundwork for this shift was laid in fiscal 2025. Revenue from continuing operations surged more than 400% to roughly C$104 million, fueled by acquisitions. On an adjusted basis, the company posted its first positive EBITDA. But under IFRS accounting standards, a net loss of about C$39 million remained—a gap that continues to give institutional investors pause.

The SpaceX Wild Card

Tucked away on the balance sheet is an unusual asset. Healwell originally invested US$2 million in a vehicle that held stakes in xAI, Elon Musk’s artificial intelligence venture. Following xAI’s integration into SpaceX, that investment is now tied to the aerospace giant. The company is actively exploring ways to monetize the holding.

Stifel analyst Justin Keywood estimates a sale could generate more than C$15 million, which would go a long way toward shoring up the balance sheet and paying down debt. Keywood currently values Healwell’s shares at 2.4 times revenue, below the 2.8 times multiple typical of comparable life-science technology firms.

Market Moves and Technical Signals

The stock has shown some life ahead of the earnings release, climbing nearly 27% over the past month to €0.58. That rally has pushed the price back above its 50-day moving average. On a longer timeframe, however, the picture is less rosy: the shares are still down almost 39% year-over-year. The relative strength index sits near 25, a level that historically suggests the stock is deeply oversold.

In contrast, the secondary article notes the stock was trading at €0.56 with a slight daily decline of about 3%, while the monthly gain was pegged at roughly 23%. The discrepancy likely reflects the timing of the reports, but both paint a picture of a stock that has recently found a bid after a prolonged slump.

What Investors Will Watch

When management hosts its investor call on May 8, the spotlight will be on commercial traction for the newly unified Amadeus AI platform. The system consolidates Healwell’s product suite under a single artificial intelligence engine, drawing on millions of patient records. A North American launch is slated for the first half of the year, with international expansion to follow.

Keywood expects Healwell to reach free cash flow break-even by the fourth quarter of 2026, contingent on organic contract wins and the successful monetization of the SpaceX-linked stake. For the current fiscal year, management is targeting roughly 50% growth in AI-related revenue and an adjusted operating margin of about 10%.

The company has also bolstered its clinical credentials with a recent peer-reviewed publication on its Darwen AI platform in a medical journal. But the conference call will focus squarely on commercial milestones: updates on the Amadeus rollout, the closing of the Canadian asset sale, and progress on unlocking the value of the SpaceX investment.